Aardvark Therapeutics Sued for Securities Law Violations
A class action lawsuit has been filed against Aardvark Therapeutics (NASDAQ: AARD) for alleged violations of federal securities laws. The company is accused of misleading investors about the commercial prospects of its ARD-101 drug candidate.
NEW YORK, Oct. 12, 2026 /PRNewswire/ -- DJS Law Group today announced a class action lawsuit has been filed against Aardvark Therapeutics, Inc. ("Aardvark" or "the Company") (NASDAQ: AARD) for alleged violations of federal securities laws. The lawsuit claims the company made false and misleading statements to the market regarding the commercial prospects of its ARD-101 drug candidate.
The class period for the lawsuit covers purchases of AARD securities made pursuant to the Company's initial public offering on February 13, 2025, and any time thereafter up to May 14, 2026. Shareholders who purchased AARD stock during this period and suffered losses are encouraged to contact the firm. Appointment as lead plaintiff is not required to participate in any recovery.
According to the Complaint, Aardvark Therapeutics made materially misleading statements regarding the commercial viability of its ARD-101 drug candidate. These statements allegedly led investors to purchase AARD stock at artificially inflated prices, resulting in financial losses for those who invested during the specified period.
The deadline for investors to seek to be appointed as lead plaintiff is October 13, 2026. DJS Law Group focuses on securities class actions and aims to recover losses for investors who have been harmed by corporate misconduct.